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A B S T R A C T
The aim of this study was to analyse breast carcinomas with discordant receptor status, probably hormonal depend-
ent (estrogen receptor (ER) positive, progesterone receptor (PR) negative or ER-PR+ subgroup profile) infiltrating ductal
breast carcinomas not otherwise specified (IDC NOS). Specimens from 90 IDC NOS were grouped into three categories
according to hormonal status: dependent (D) (ER+PR+), probably dependent (PD) (ER+PR- or ER-PR+) and non-de-
pendent (ND) (ER-PR-); they were evaluated considering some established prognostic parameters in breast carcinomas.
Statistically significant difference was found between tumor receptor status distribution and menopausal status (p=
0.0235), age of the patients (p=0.000467), histological grade (p=0.000003), vascular invasion (p=0.006), HER-2 status
(p=0.0039) and Ki-67 proliferation rate (p=0.000311). D tumors were found exclusively in post-menopausal patients
(average age 68.9 years), most of which had intermediate (II) grade, without vascular invasion, with HER-2 status score
predominantly 0 or 1+ and lower Ki-67 proliferation rate. PD tumors were found predominantly in younger post-meno-
pausal patients (average age 57.5 years), with vascular invasion found in 23% of the cases. ND tumors mostly had higher
histological grade, showed the highest percentage of the Ki-67 positive tumor cells and vascular invasion in 30% of the
cases. We conclude that the patients with PD breast carcinomas were younger post-menopausal women with the tumors
moderately differentiated, HER-2 score 0 or 1+ and with lower Ki-67 proliferation rate.
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Introduction
Since the discovery of the estrogen receptors (ER) in
1960, they have become one of the most important prog-
nostic and predictive markers for breast cancer1. The
presence of both ER and progesterone receptors (PR) is
related to better prognosis and responsiveness to hor-
monal therapy2. Proper understanding of prognostic fea-
tures of breast cancer can help physicians in the selection
of the appropriate treatment for the individual patient.
These features are lymph node involvement, tumor size
and grade, status of estrogen receptor (ER) and proges-
terone receptor (PR), status of the biological marker
HER2/neu gene expression profile, and patient’s age3.
Thorpe S.M. has argued that all ER-PR+ tumors should
be regarded as biologically equivalent to ER+PR+ tu-
mors. However, the response rate to hormonal therapy
for ER-PR+ tumors is substantially lower than for ER+
PR+ tumors, suggesting real differences between the
two hormone receptor profiles4–6.
The aim of this study is to reconsider discordant re-
ceptor status breast cancers with probably dependent
hormonal status (ER+PR- or ER-PR+ subgroup profile)
and compare their expression and some established prog-
nostic parameters in breast cancer, i.e. tumor size, lymph
node metastases, histological and nuclear grade, meno-
pausal status, age of the patients, Ki-67 proliferation in-
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dex and HER-2 receptor status. The subsets of breast
cancer patients that we would seek according to hor-
monal status are those which are supposed to have less
favourable prognosis and higher metastatic potential.
Materials and methods
Study population
Breast cancer tissue was obtained from surgical speci-
mens submitted to Department of Pathology, University
School of Medicine Rijeka, during a two-year period
(from September 1st 2002 to August 31st 2004). Among
them, 90 cases of IDC NOS were studied. The histology
of each case was reviewed and the tumors were classified
according to the WHO criteria. Tumors were grouped
into three categories according to their hormonal status:
dependent (D) (ER+PR+), probably dependent (PD)
(ER+PR- or ER-PR+) and non-dependent (ND) (ER-PR-).
The age of the patients at the time of surgery was taken
into account, and menopausal status was defined clini-
cally according to the regularity of menstrual cycle.
Histopathological examination
After formalin fixation, paraffin embedding and sta-
ining with hematoxylin/eosin, histopathological features
were determined by pathologist prior to the immuno-
histochemical examination. Histological grade was as-
sessed using Bloom and Richardson’s method, modified
by Elson and Ellis7.
Immunohistochemistry
Three-micrometer sections were mounted on DAKO
Chem Mate slides (Code No. S2024), deparaffinised and
rehydrated in graded alcohols. Epitope retrieval was car-
ried out on 0.01 M citrate buffer (pH 6.0) in water bath at
97°C for 40 minutes. The slides were then incubated with
the primary antibody provided with the Kit, in a DAKO
TechMate Horizon automated immunostainer (LJL Bio-
systems Inc, Sunnyvale, USA). 3,3 diamino-bensidin was
used as the chromogen. Substitution of the primary anti-
body with an isotype matched IgG and omission of the
primary antibody served as negative controls.
ER and PR receptors
The samples were stained by anti-receptor antibody;
monoclonal mouse antibody, anti-human estrogen recep-
tor a (Clone 1D5, isotype IgG1-kappa, DakoCytomation,
Glostrup, Denmark) (dilution 1:50) and monoclonal mo-
use antibody, anti-human progesterone receptor (Clone
PgR 636, isotype IgG1-kappa, DakoCytomation, Glost-
rup, Denmark) (dilution 1:50). Previously identified stron-
gly staining tumor tissue sections served as positive con-
trols. ER and PR status were expressed in the form of
H-score8, based on a summation of the proportion of tu-
mor cells, showing different degrees of reactivity: nega-
tive=0 (0–50), weak=1 (51–100), moderate=2 (101–200),
strong=3 (201–300). This gives a maximum total score of
300 if 100% of cells show strong reactivity. In PD group
we evaluated weak and moderate positive (ER+PR- or
ER-PR+) reactivity of tumor cells (Figure 1a and b).
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Fig 1. Invisive duct carcinoma, immunostaining for: a) estrogen receptor (ER), b) progesterone receptor (PR),
c) proliferation marker Ki-67, d) HER2/neu receptor.
Ki-67 proliferation index
Staining was obtained by monoclonal mouse antibody,
anti Ki-67 (Clone Ki-S5, DAKO, Carpinteria, USA) (dilu-
tion 1:50) using the labelled streptavidin biotin (LSAB)
visualization system (DAKO Chem Mate Detection Kit,
No.5001). Positive staining of chromatin in dividing cells
served as internal positive control. Ki-67 proliferation in-
dex was expressed as a percentage of positive cells on to-
tal of 1000 tumor cells counted. Tumor cells displaying a
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TABLE 1
CLINICOPATHOLOGICAL BACKGROUND FACTORS FOR IMMUNOHISTOCHEMICALLY DETERMINED HORMON
AL STATUS OF 90 BREAST CANCER PATIENTS
No. of patients (n=90)
Hormonal status Dependent n=30 Probably dependent n=30 Not dependent n=30
Menopausal status
Pre-menopausal
Post-menopausal
0
30
7
23
5
25
Age (years) 68.9 ± 8.3 57.5 ± 13.5 59.7 ± 12.1
Tumor size (cm) 2.22 ± 1.36 2.3 ± 2.32 3.47 ± 3.54
Type of tumor growth
Expansive
Infiltrating
10
20
9
21
10
20
Histological grade*
I
II
III
11
19
0
7
18
5
3
9
18
Peritumoral lymphatic vessel invasion
negative
positive
17
13
14
16
12
18
Intratumoral lymphatic vessel invasion
negative
positive
27
3
27
3
25
5
Vascular invasion
negative
positive
30
0
23
7
21
9
Lymphocyte infiltration
negative
positive
2
28
3
27
2
28
Pathological lymph node status**
pN0
pN1
pN2
pN3
pN1mi
23
1
3
1
2
22
4
2
2
0
17
1
7
4
1
Expression of HER2***
0
1
2
3
13
14
3
0
14
10
2
4
10
5
3
12
Ki-67 expression (% of positive cells) 14.64 12.91 28.85
* I- well diferentiated, II- intermediate, III- poorly diferentiated
** pN – Regional Lymph Nodes, pN0 – No regional lymph node metastasis, pN1 – Metastasis in 1–3 ipsilateral axillary lymph node(s),
and/or in internal mammary nodes with microscopic metastasis detected by sentinel lymph node dissection but not clinically apparent,
pN2 – Metastasis in 4–9 ipsilateral axillary lymph nodes or in clinically apparent ipsilateral internal mammary lymph node(s) in the
absence of axillary lymph node metastasis, pN3 – Metastasis in 10 or more ipsilateral axillary lymph nodes; or in infraclavicular lymph
nodes; or in clinically apparentipsilateral internal mammary lymph nodes in the presence of one or more positive axillary lymph nodes;
or inmore than 3 axillary lymph nodes with clinnically negative, microscopic metastasis in internal mammary lymph nodes; or in ipsilateral
supraclavicular lymph nodes, pN1mi – Micrometastasis (larger than 0.2 mm, but none larger than 2 mm in greatest dimension)
*** 0 – negative, 1 – weakly positive, 2 – moderately positive, 3 – strongly positive
nuclear staining were considered positive. Briefly, the
sections were deparaffinized with xylene and rehydrated
in graded alcohols, followed by the antigen retrieval pro-
cess (heat-induced epitope retrieval) and primary anti-
body retrieval, using the microwave and citrate buffer
pH 6.1 (Code No. S2031, DakoCytomation). After that,
slides were put in the DAKO TechMate Horizon auto-
mated immunostainer (LJL Biosystems Inc, Sunnyvale,
USA) and the Microwave streptavidin immunoperoxi-
dase (MSIP) protocol was followed. 3,3 diamino-bensidin
was used as the chromogen.
HER-2 receptors
HER-2 immunostaining was performed using poly-
clonal prediluted rabbit anti-human HER-2 protein anti-
body (provided with the HercepTest K5206, DakoCyto-
mation, Glostrup. Denmark). HER-2 status was assessed
by a score that includes the intensity and the percentage
of positive tumor cells as 0 (negative), 1+, 2+ and 3+
(strongly positive). Only membrane HER-2 immunosta-
ining was considered positive. Previously identified stron-
gly staining tumor tissue sections were used as positive
controls.
Statistics
Various methods of descriptive and analytic biomedi-
cal statistics were used. Pearson X2 and ANOVA were
used in comparison analysis of various histopathological
features between the three groups (D, PD, ND) and
Kendall Tau Correlation test was used for correlation
analyses. Statistical differences with p value < 0.05 were
considered significant. The data was analyzed by SPSS
PACKAGE Release 6.0 for PC (SPSS Inc, Chicago, USA).
Results
The age of the patients at the time of surgery ranged
from 30 to 87, with a median age of 63 years. There were
12 pre-menopausal and 78 post-menopausal women in
our study population, 62 without lymph node involve-
ment and 28 with lymph node metastasis. Clinicopatho-
logical features of tumors were summarized in Table 1.
We found a statistically significant difference between
tumor receptor status distribution and menopause (p=
0.024), age of the patients (p=0.001), histological grade
(p=0.001), vascular invasion (p=0.006), HER-2 status
(p=0.004) and Ki-67 expression (p=0.001). D tumors
were found exclusively in post-menopausal women, (av-
erage age 68.9 years). Most of these tumors had interme-
diate (II) grade, showed no vascular invasion, HER-2 sta-
tus score was predominantly 0 or 1+ and Ki-67 proli-
feration rate was lower. PD and ND tumors were found
among both post- and pre-menopausal women with lower
average ages (57.5 and 59.7 years, consecutively). The
vascular invasion was found at 23% of PD and 30% of ND
tumors, while most of the ND tumors had higher histolo-
gical grade, showed the highest Ki-67 expression (Figure
1c) and HER-2 status score 3+ was found at 40% of these
tumors (Figure 1d).
There was no statistically significant difference be-
tween tumor receptor status distribution and tumor size
(p=0.11), lymph node status (p=0.17), number of the
positive lymph nodes (p=0.77), perinodal infiltration
(p=0.43), findings in peritumoral breast tissue (p=0.71),
peritumoral (p=0.43) and intratumoral (p=0.66) lym-
phatic invasion, lymphocyte infiltration (p=0.856) and
type of tumor invasion (p=0.95). The coefficient of con-
tingency found no statistically significant difference in
tumor size among PD, ND and D tumors, although the
ND tumors were bigger, had higher percentage (22.4%)
of the positive lymph nodes out of totally removed axi-
llary lymph nodes than PD (16.8%) and D (17.4%) tu-
mors. Invasion at the peritumoral and intratumoral lym-
phatic vessels occurred more frequently. Type of the
tumor growth in 70% of the cases was with infiltrating
borders.
Discussion
It is well known that breast cancer depends on vari-
ous clinicopathological factors, including: metastatic sta-
tus of the lymph nodes, tumor size, tumor grade, histolo-
gical grade, HER-2 status and proliferation markers such
as Ki 67. We raised the question weather the hormone re-
ceptor status of these patients could influence these
parameters9.
Despite the fact that there is a higher absolute age-
-specific incidence of breast cancer in post- rather than in
pre-menopausal women, the dramatic slowing of its in-
crease rate with age suggests a major role of the ovarian
activity in its development. As the growth of breast can-
cer is often regulated by female sex steroids, determina-
tions of the cellular concentrations of ER and PR in the
tumor are currently used to predict which patients are of
good prognosis and may also benefit from antihormonal
therapy10. Although more than 60% of human breast
cancers are ER-positive, no more than two-thirds of
these ER-positive tumors respond to endocrine thera-
py11. It is of interest that both ER and PR appear to be
strongly up-regulated in hormone-dependent breast can-
cer in relation to normal mammary epithelium. It is not
clear, yet, what is the exact relationship between ER+
and ER- forms of the disease. Some studies have shown
that ER-negative breast cancer cell lines do not tran-
scribe the ER mRNA due to an extensive methylation of
the 5’promoter of the gene thus loosing the estrogene re-
ceptor expression in human breast cancer cells12. The
central question in breast cancer research focuses on
mechanisms of desensitization of the disease to anti-
hormonal therapy and design of strategies to maintain
antihormonal responses in patients. Measurement of PR
improves the predictability of hormone dependency of a
tumor, but this relationship remains imperfect. Retro-
spective clinical studies have demonstrated that only
70% of PR-positive and 25–30% of PR-negative tumors
respond to hormonal therapy13. Still, the ER and PR sta-
tus at the time of breast carcinoma surgery is used as a
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marker of both prognosis and hormone dependency to
guide adjuvant therapy14,15.
The ER positivity is strongly associated with the age
at diagnosis, being more prevalent among post-meno-
pausal women16,17. In our report, the hormonally depend-
ent patients were exclusively post-menopausal with aver-
age age of 68.9 years. According to the last data obtained
from Croatian Cancer Registry, the average age of breast
cancer patients in Croatia is among 50–69 years. It could
be speculated that the increased ER content during me-
nopause might be due to a decreased level of estrogens
and the fact that cyclical progesterone secretion in pre-
-menopausal women limits estrogen stimulation of ER
synthesis. A possible explanation of the lower percentage
of ER positivity in pre-menopausal patients could be a
blockade of ER by endogenous estrogens14. It could also
be hypothesized that the differences in ER and PR status
between pre- and post-menopausal women might be due
to a distinct tumor biology and, thus, may truly reflect
the differences in its hormone dependency.
It is well known that breast tumors are less well-dif-
ferentiated among younger women. In an evaluation of
breast cancer in women 35 years of age or younger, Rosen
et al. found a high incidence of poorly differentiated tu-
mors (53%), and ER-negative carcinomas18,19. Our ND
patients had the average age of 59.7 years, while PD pa-
tients had the average age of 57.5 years. Kollias et al. re-
ported similar findings in an evaluation of 2897 women
with breast cancer; higher nuclear grade and lympho-
vascular invasion observed in women younger than 35
years of age when compared with older women20.
Our group of ND tumors was predominantly poorly
differentiated (60% of them), while in group of D tumors
this category was not observed (the tumors were moder-
ately differentiated in 63.33% of cases).The D tumors
were mostly of grade II (63.33% of them), and there was
no grade III present. Mink et al. showed no correlation
between steroid hormone receptor expression and grad-
ing, but they showed a slight decrease of ER positive can-
cers with increasing tumor size21.
We observed the intratumoral lymphatic invasion in
the similar percentage of all three groups of tumors
(10–17%). According to our results, the peritumoral lym-
phatic invasion was slightly higher in ND group, but
without statistical significance. Lymphocytes infiltration
was also similar in all three groups (X2=0.3; p=0.856).
Vascular invasion was not present in D tumors, while in
other two groups it was present in 23% and 30% respec-
tively. The analyzed tumors mostly showed infiltrating
borders (in 70% of our cases). Their size was not statisti-
cally significantly different in analyzed groups (F=2.22;
p=0.11). It is known that in patients with small tumors
treated with adjuvant hormonal therapy the survival was
significantly longer22. We also found no difference in the
changes of the surrounding breast tissue in all three
groups.
HER-2 gene amplification or protein over-expression
is evident in 20–30% of human breast tumors and corre-
lates with poor prognosis23,24. The reason for this associa-
tion remains unclear, although it has been suggested to
rest in increased proliferation, vessel formation and/or
invasiveness25. In our study, the group of ND tumors had
the HER-2 score 3+ in 40% of cases; the fact we didn’t
observe in D and PD groups of tumors. In this group of
tumors there was also a strong correlation between the
HER-2 receptors expression and Ki-67 (p=0.025). Once
again, we observed that the ND tumors showed the high-
est Ki-67 proliferation rate (x=28.85%, S=21.58). So, the
poor clinical outcome of these breast cancer patients is
expected. Lukashina et al. showed that the higher Ki-67
expression was more frequently associated with positive
expression of HER-2/neu. Thus, aneuploid tumors with
higher proliferative activity and hyper-expression of
HER-2/neu are more aggressive ones and larger in size26.
The use of Herceptin (the humanized HER-2/neu an-
tibody) has been effective in 20–25% of HER-2/neu posi-
tive breast cancer patients, but Witters showed that the
pre-menopausal women with HER-2/neu over expression
and ER-positive breast tumors would probably receive
little benefit, and possibly detrimental effects, from treat-
ment with a HER-2/neu inhibitor alone27,28.
The status of the axillary lymph nodes is one of the
most important prognostic factors in patients with breast
cancer. Bader et al. showed that approximately 13% of
patients with well or moderately differentiated tumors,
less than or equal to 1 cm in size, without lymph or vas-
cular invasion and a low Ki-67 expression had a low risk
of axillary lymph node metastases (4.3%)29. We observed
no statistical difference in the number of positive axillary
lymph nodes in three groups that had been investigated
(X2=1.5; p=0.17). It had previously been shown that, if
the positive axillary lymph nodes correlated with HER-2
over-expression, the prognosis was poor24. According to
Collett et al, PR and ER status predicted prognosis in
middle age patients (40–60 years) with lymph node posi-
tive breast cancer. Analyzing the number of perinodal in-
filtrations regarding the total number of positive lymph
nodes, we found no significant difference among the
three tumor groups30.
In our report, discordant receptor breast carcinomas
with PD hormonal status (ER+PR- or ER-PR+ sub-
group) were found predominantly in younger post-meno-
pausal women, (approximately 10-years younger than
women with D tumors), mostly with intermediate (II)
histological grade, HER-2 status 0 or 1+ and lower Ki-67
proliferation rate. Our results of ER+PR- suggest, as
previously shown22, the existence of functionally inactive
variants of ER.
We suggest the clinical importance of our results. The
patients with D tumors should be primarily candidates
for hormonal therapy, especially in old age, while more
aggressive PD and especially ND tumors should be tre-
ated with proper chemotherapy regimens that should
give a possibility of lasting remission.
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DUKTALNI INVAZIVNI RAK DOJKE: ANALIZA HORMONSKIH, HER-2 RECEPTORA
I KI-67 PROLIFERACIJKOG BILJEGA
S A @ E T A K
Cilj ove studije je analiza invazivnog duktalnog karcinoma dojke (tip bez drugih osobitosti-BDO) s razli~itim statu-
som receptora, vjerojatno hormonski ovisni (estrogen receptor (ER) pozitivan, progesteron receptor(PR) negativan ili
ER-PR+ podgrupa profil). Uzorci od 90 karcinoma su grupirani u tri kategorije prema hormonskom statusu: ovisni
(ER+PR+), vjerojatno ovisni (ER+PR- ili ER-PR+) i neovisni (ER-PR-); i evaluirani s obzirom na dokazane prognosti-
~ke ~imbenike karcinoma dojke. Statisti~ka zna~ajnost je na|ena izme|u distribucije tumorskih receptora i menopau-
zalnog statusa (p=0,0235), starosti pacijentica (p=0,000467), histolo{kog stupnja (p=0,000003), vaskularne invazije
(p=0,006), izra`ajnost HER-2 statusa (p=0,0039) i Ki-67 proliferacijskog biljega (p=0,000311).Hormonski ovisni tu-
mori su na|eni isklju~ivo kod postmenopauzalnih pacijentica (prosje~na dob 68,9 godina), ve}ina ih je bila umjerenog
(II) histolo{kog stupnja, bez vaskularne invazije, sa HER-2 statusom predominantno 0 ili 1+ i ni`e izra`ajnost Ki-67
proliferacijskog biljega. Vjerojatno hormonski ovisni tumori su na|eni isklju~ivo u mla|ih postmenopauzalnih pacijen-
tica (prosje~na dob 57,5 godina), s vaskularnom invazijom u 23 % slu~ajeva. Hormonski neovisni tumori uglavnom su
imali vi{i histolo{ki stupanj, pokazuju visoki postotak izra`ajnosti Ki-67 biljega i vaskularnu invaziju u 30% slu~ajeva.
Zaklju~ujemo da pacijentice s vjerojatno hormonski ovisnim karcinomima su mla|e postmenopauzalne `ene s umjereno
diferenciranim tumorima, koji su s HER-2 statusom 0 ili 1+ i manjim Ki-67 proliferacijskim indeksom.
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